Evidence map›Paper›PMID 34867794›Full record

Trial reportFrontiers in endocrinology2021

24-Hour Profiles of 11-Oxygenated C

Adina F Turcu, Ashwini Mallappa, Aikaterini A Nella, Xuan Chen, Lili Zhao, Aya T Nanba, James Brian Byrd, Richard J Auchus, Deborah P Merke

Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph

Trial report in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Approach to the Child and Adolescent With Adrenal Insufficiency.The Journal of clinical endocrinology and metabolism · 2025
    Review
  5. Review
  6. Review
  7. The role of 11-oxygenated androgens in prostate cancer.Endocrine oncology (Bristol, England) · 2023
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Adina F TurcuDivision of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, United States.
Ashwini MallappaPediatric Service, National Institutes of Health (NIH) Clinical Center, Bethesda, MD, United States.
Aikaterini A NellaDivision of Pediatric Diabetes and Endocrinology, Baylor College of Medicine, Houston, TX, United States.
Xuan ChenSchool of Public Health, University of Michigan, Ann Arbor, MI, United States.
Lili ZhaoSchool of Public Health, University of Michigan, Ann Arbor, MI, United States.
Aya T NanbaDivision of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, United States.
James Brian ByrdDivision of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, United States.
Richard J AuchusDivision of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, United States.
Deborah P MerkePediatric Service, National Institutes of Health (NIH) Clinical Center, Bethesda, MD, United States.
University of Michigan–Ann Arbor · USBaylor College of Medicine · USEunice Kennedy Shriver National Institute of Child Health and Human Development · USNational Institutes of Health Clinical Center · US

Funding

Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
Activation of androgen biosynthesis and drug metabolism by cytochrome b5R01GM086596 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI RICHARD J. AUCHUS · 2009 to 2026
$4.8M
A Novel Biomarker of Mineralocorticoid Receptor ActivationK23HL128909 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BYRD, JAMES BRIAN · 2016 to 2020
$972k
The contemporary endocrinology of congenital adrenal hyperplasiaK08DK109116 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TURCU, ADINA F · 2016 to 2020
$832k
NHLBI NIH HHS K23 HL128909NIDDK NIH HHS K08 DK109116NIDDK NIH HHS P30 DK092926NIGMS NIH HHS R01 GM086596
6 · The paper itself

Abstract

Background: Optimal management of androgen excess in 21-hydroxylase deficiency (21OHD) remains challenging. 11-oxygenated-C Objective: To compare the dynamic response of a broad set of steroids to both conventional oral glucocorticoids (OG) and circadian cortisol replacement Participants and Methods: We studied 8 adults (5 women), ages 19-43 years, with poorly controlled classic 21OHD who participated in a single-center open-label phase I-II study comparing OG with CSHI. We used mass spectrometry to measure 15 steroids (including 11-oxyandrogens and Δ Results: In response to OG therapy, androstenedione, testosterone (T), and their four 11-oxyandrogen metabolites:11β-hydroxyandrostenedione, 11-ketoandrostenedione, 11β-hydroxytestosterone and 11-ketotestosterone (11KT) demonstrated a delayed decline in serum concentrations, and they achieved a nadir between 0100-0300. Unlike DHEAS, which had little diurnal variation, pregnenolone sulfate (PregS) and 17-hydoxypregnenolone sulfate peaked in early morning and declined progressively throughout the day. CSHI dampened the early ACTH and androgen rise, allowing the ACTH-driven adrenal steroids to return closer to baseline before mid-day. 11KT concentrations displayed the most consistent difference between OG and CSHI across all time segments. While T was lowered by CSHI as compared with OG in women, T increased in men, suggesting an improvement of the testicular function in parallel with 21OHD control in men. Conclusion: 11-oxyandrogens and PregS could serve as biomarkers of disease control in 21OHD. The development of normative data for these promising novel biomarkers must consider their diurnal variability.

Indexed as

Adrenal Hyperplasia, CongenitalAdultBiomarkersCircadian RhythmFemaleGlucocorticoidsHumansHydrocortisoneMaleSteroidsSulfatesYoung AdultBiomarkersGlucocorticoidsHydrocortisoneSteroidsSulfates11-oxyandrogens21-hydroxylase deficiencyCAHCircadian hormonescongenital adrenal hyperplasiacortisol 24-hour profile

Identifiers

PMID34867794
PMCPMC8636728
OpenAlexW3211757894

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.